COSCIENS Biopharma (CSCI) Competitors $4.05 +0.21 (+5.47%) Closing price 07/17/2025 03:59 PM EasternExtended Trading$4.05 0.00 (0.00%) As of 07/17/2025 06:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesSEC FilingsTrendsBuy This Stock CSCI vs. MURA, ELYM, BRNS, MRSN, PEPG, LTRN, MDCX, ACRV, ATHE, and PLURShould you be buying COSCIENS Biopharma stock or one of its competitors? The main competitors of COSCIENS Biopharma include Mural Oncology (MURA), Eliem Therapeutics (ELYM), Barinthus Biotherapeutics (BRNS), Mersana Therapeutics (MRSN), PepGen (PEPG), Lantern Pharma (LTRN), Medicus Pharma (MDCX), Acrivon Therapeutics (ACRV), Alterity Therapeutics (ATHE), and Pluri (PLUR). These companies are all part of the "pharmaceutical products" industry. COSCIENS Biopharma vs. Its Competitors Mural Oncology Eliem Therapeutics Barinthus Biotherapeutics Mersana Therapeutics PepGen Lantern Pharma Medicus Pharma Acrivon Therapeutics Alterity Therapeutics Pluri Mural Oncology (NASDAQ:MURA) and COSCIENS Biopharma (NASDAQ:CSCI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and media sentiment. Do analysts recommend MURA or CSCI? Mural Oncology presently has a consensus target price of $12.00, indicating a potential upside of 381.93%. Given Mural Oncology's stronger consensus rating and higher possible upside, equities research analysts clearly believe Mural Oncology is more favorable than COSCIENS Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mural Oncology 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50COSCIENS Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is MURA or CSCI more profitable? Mural Oncology has a net margin of 0.00% compared to COSCIENS Biopharma's net margin of -194.50%. Mural Oncology's return on equity of -83.39% beat COSCIENS Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Mural OncologyN/A -83.39% -70.70% COSCIENS Biopharma -194.50%-101.01%-43.90% Does the media favor MURA or CSCI? In the previous week, Mural Oncology's average media sentiment score of 1.89 beat COSCIENS Biopharma's score of 1.87 indicating that Mural Oncology is being referred to more favorably in the media. Company Overall Sentiment Mural Oncology Very Positive COSCIENS Biopharma Very Positive Which has higher valuation and earnings, MURA or CSCI? COSCIENS Biopharma has higher revenue and earnings than Mural Oncology. COSCIENS Biopharma is trading at a lower price-to-earnings ratio than Mural Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMural OncologyN/AN/A-$128.51M-$7.67-0.32COSCIENS Biopharma$9.59M1.33-$15.31M-$5.80-0.70 Do insiders & institutionals believe in MURA or CSCI? 80.2% of Mural Oncology shares are held by institutional investors. Comparatively, 0.7% of COSCIENS Biopharma shares are held by institutional investors. 2.2% of Mural Oncology shares are held by company insiders. Comparatively, 0.1% of COSCIENS Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has more risk & volatility, MURA or CSCI? Mural Oncology has a beta of 3.03, meaning that its stock price is 203% more volatile than the S&P 500. Comparatively, COSCIENS Biopharma has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500. SummaryMural Oncology beats COSCIENS Biopharma on 10 of the 14 factors compared between the two stocks. Get COSCIENS Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CSCI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CSCI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CSCI vs. The Competition Export to ExcelMetricCOSCIENS BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.08M$2.94B$5.57B$9.34BDividend YieldN/A2.45%3.80%4.06%P/E Ratio-0.7020.2928.1019.86Price / Sales1.33302.32441.4199.92Price / CashN/A43.1635.8457.94Price / Book1.167.838.265.67Net Income-$15.31M-$55.11M$3.24B$257.80M7 Day Performance17.60%3.21%1.48%1.87%1 Month Performance15.06%12.86%8.07%10.92%1 Year PerformanceN/A5.06%30.29%18.51% COSCIENS Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CSCICOSCIENS BiopharmaN/A$4.05+5.5%N/AN/A$12.08M$9.59M-0.7020Positive NewsMURAMural Oncology3.4562 of 5 stars$2.49-2.0%$12.00+381.9%-28.4%$43.00MN/A-0.32119Positive NewsELYMEliem TherapeuticsN/A$1.42+3.6%N/A-79.6%$42.25MN/A-2.689BRNSBarinthus Biotherapeutics3.2607 of 5 stars$1.02flat$6.25+512.7%+2.0%$41.15M$14.97M-0.62107News CoverageGap DownMRSNMersana Therapeutics4.2015 of 5 stars$0.33-4.9%$5.20+1,494.6%-83.2%$40.64M$40.50M-0.55150Positive NewsPEPGPepGen3.2577 of 5 stars$1.24-3.9%$7.67+518.3%-92.4%$40.57MN/A-0.4030LTRNLantern Pharma3.0295 of 5 stars$3.76-5.8%$25.00+564.9%-11.4%$40.53MN/A-2.0420High Trading VolumeMDCXMedicus Pharma2.2427 of 5 stars$2.97-5.1%$23.50+691.2%N/A$40.30MN/A-2.56N/AHigh Trading VolumeACRVAcrivon Therapeutics3.9283 of 5 stars$1.28-3.8%$17.71+1,283.9%-82.8%$40.13MN/A-0.5858Positive NewsATHEAlterity Therapeutics2.2081 of 5 stars$4.47-3.5%$12.00+168.5%+115.4%$39.65MN/A0.0010Gap DownPLURPluri3.5786 of 5 stars$5.02-1.2%$12.00+139.0%-5.6%$39.32M$1.03M-0.91150Positive NewsGap DownHigh Trading Volume Related Companies and Tools Related Companies MURA Competitors ELYM Competitors BRNS Competitors MRSN Competitors PEPG Competitors LTRN Competitors MDCX Competitors ACRV Competitors ATHE Competitors PLUR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CSCI) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersElon Just Fired the IRS Agents Targeting Your SavingsElon Musk just fired 6,700 IRS agents — and exposed a war on your retirement. While D.C. scrambles to regai...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding COSCIENS Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share COSCIENS Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CSCI Stock Alerts